Key Takeaways
- CVS Health posted 2024 sales guidance Tuesday that beat estimates and raised its dividend as it reported that demand for its health-care services increased.
- CVS also introduced plans to change the way prescription drug reimbursement works.
- CVS shares advanced on the news Tuesday, but they remain lower for 2023.
CVS Health (CVS) shares jumped about 4% T🅘uesday after the drugstore chain and health-care firm posted strong guidance and raised its dividend on rep꧃orted higher demand for its health-care services.
CVS projected that 2024 revenue would be at least $366.0 billion, well above analysts’ estimates of $344.5 billion. The company also said it would increase its quarterly dividend to 66.5 cents a share from 60.5 cents per share, payable Feb. 1 , 2024, to shareholders of record Jan. 22 of that year.
In addition, CVS announced several initiatives. It said its CVS CostVantage plan will be a new aജpproach to the traditional phaꦅrmacy reimbursement model that will bring “greater transparency and simplicity to the system.”
Along with that, the company introduced TrueCost, which it said “offers client pricing reflecting the true net 澳洲幸运5开奖号码历史查询:cost of prescription drugs, with visibility into administrative fees.”
CVS is also launching CVS Healthspire, the new brand name for its health-care segment, which includes Caremark, Cordavis, 澳洲幸运5开奖号码历史查询:Oak Street Health, Signify Health, and MinuteClinic.
Despite Tuesday’s gains, shares of CVS 𝐆H🥃ealth are down about 23% for the year to date.
:max_bytes(150000):strip_icc()/CVS_2023-12-05_12-31-28-a43d93e797954e418a82a423e1bf3fbd.png)
TradingView